门诊EEG (aEEG) 在管理中的独特地位
Hardik Doshi1, Richa Tripathi2, Zainab Alalawi3
1Virginia Commonwealth University, Richmond VA, USA.
Epilepsy & behavior : E&B
|June 4, 2025
概括
门诊EEG (aEEG) 捕获的发作和间发作性放电 (IED) 比以前想象的要多,有助于患者的抗药物 (ASD) 戒断决策. 这项技术有助于揭示比临床报告更高的发作负担.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 临床神经生理学 临床神经生理学
背景情况:
- 治疗通常依赖于患者报告的发作频率,这可能低估了真正的发作负担.
- 门诊电脑图 (aEEG) 提供了一种连续监测解决方案,可以捕捉标准方法遗漏的亚临床事件.
研究的目的:
- 评估出行式EEG (aEEG) 在检测和非事件中的诊断收益率.
- 为了比较aEEG的产量与传统的长期住院视频EEG (rEEG) 的产量,以捕捉间触发性发性放电 (IED).
- 评估aEEG在指导抗发作药物 (ASD) 戒断的有用性,在至少两年没有发作的患者中.
主要方法:
- 对309名在1.5年内接受EEG治疗的患者进行了回顾性图表审查.
- 通过日志记录"事件"的记录,收集数据,包括患者人口统计数据,发作频率,ASD和EEG发现 (aEEG和之前的rEEG).
- 对随访临床笔记的审查,以确定EEG发现对临床决策的影响.
主要成果:
- aEEG在3%的患者中捕获了电图发作,在14名患者中捕获了非性事件;然而,只有20%的捕获的发作被记录.
- 对于检测IED的aEEG的收益率为29%,在59%的案例中显示了比以前的rEEG更高的检测率.
- 在接受ASD戒断的患者中,在50%的罕见IED患者和21%的非型EEG患者中观察到发作复发.
结论:
- 患者报告的发作频率往往低估了实际的发作负担,强调了仅基于口头报告的临床决策的局限性.
- 门诊EEG (aEEG) 可以更准确地估计未被识别的和IED.
- aEEG发现可以在指导关于抗发作药物 (ASD) 戒断的决策中具有价值,可能改善患者管理和结果.
相关概念视频
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
637
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
637
Antiepileptic Drugs: Glutamate Antagonists
906
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
906
Electroconvulsive Therapy
927
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
927
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
834
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
834
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K


